The Chase virus represents a 'prime strain' of rhinovirus type 22, as its immune serum can neutralize both prototype and variant strains.
Answers are grounded in this paper and cite their sources.
May guide rhinovirus antigenic assays; leaves open human vaccine relevance.
Seventeen of eighteen type 22 rhinoviruses isolated in this laboratory were shown to be antigenic variants of the prototype strain (127-CV22). The variant viruses were neutralized poorly or not at all by immune serum to the prototype strain. However, immune serum prepared to one of the variant viruses (Chase) neutralized both the prototype and homologous strains to similar titer and also neutralized all of the other isolates. The neutralizing reactivity of the Chase virus immune serum for the prototype and homologous strains was found to be essentially unaltered by multiple absorptions with human liver powder, a procedure capable of removing cytoxic factors or nonspecific inhibitors found in certain rhinovirus antisera. The Chase virus thus appears to represent a “prime strain” of rhinovirus type 22.
No takes yet. Share an insight, caveat, or question.
Schieble et al. (1970) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: